The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation
Dina Baier(University of Vienna), Walter Berger(Comprehensive Cancer Center Vienna)
Cited by 37
Related Papers
EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance
|Journal of Experimental & Clinical Cancer Research|2015|75
Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis
|Oncotarget|2013|57
Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition
|Journal of Experimental & Clinical Cancer Research|2017|38